<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Reumatologia</journal-id><journal-id journal-id-type="iso-abbrev">Reumatologia</journal-id><journal-id journal-id-type="pmc-domain-id">2980</journal-id><journal-id journal-id-type="pmc-domain">reumatol</journal-id><journal-id journal-id-type="publisher-id">RU</journal-id><journal-title-group><journal-title>Reumatologia</journal-title></journal-title-group><issn pub-type="ppub">0034-6233</issn><issn pub-type="epub">2084-9834</issn><publisher><publisher-name>Termedia Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12138994</article-id><article-id pub-id-type="pmcid-ver">PMC12138994.1</article-id><article-id pub-id-type="pmcaid">12138994</article-id><article-id pub-id-type="pmcaiid">12138994</article-id><article-id pub-id-type="pmid">40485950</article-id><article-id pub-id-type="doi">10.5114/reum/200527</article-id><article-id pub-id-type="publisher-id">200527</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Triple positivity for autoantibodies in patients with rheumatoid arthritis is associated with a severe course of the disease but not with bone turnover markers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Budlewski</surname><given-names initials="T">Tomasz</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7343-8551</contrib-id><name name-style="western"><surname>Sarnik</surname><given-names initials="J">Joanna</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3885-8497</contrib-id><name name-style="western"><surname>Brzezi&#324;ska</surname><given-names initials="O">Olga</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lewandowska-Polak</surname><given-names initials="A">Anna</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2300-7339</contrib-id><name name-style="western"><surname>Pop&#322;awski</surname><given-names initials="T">Tomasz</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2036-375X</contrib-id><name name-style="western"><surname>Makowska</surname><given-names initials="J">Joanna</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><aff id="aff0001"><label>1</label>Department of Rheumatology, Medical University of Lodz, Poland</aff><aff id="aff0002"><label>2</label>Department of Pharmaceutical Microbiology and Biochemistry, Medical University of Lodz, Poland</aff></contrib-group><author-notes><corresp id="cor1"><bold>Address for correspondence</bold> Joanna Makowska, Department of Rheumatology, Medical University of Lodz, 113 Stefana &#379;eromskiego St., 90-543 Lodz, Poland. e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="joanna.makowska@umed.lodz.pl">joanna.makowska@umed.lodz.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>63</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">489984</issue-id><fpage>81</fpage><lpage>88</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-09 15:25:52.097"><day>09</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2025 Termedia &amp; Banach</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="RU-63-200527.pdf"/><abstract><sec id="s1"><title>Introduction</title><p>Rheumatoid arthritis (RA) is a prevalent autoimmune disorder characterized by chronic joint inflammation and progressive bone erosion. Traditional autoantibodies, such as anti-citrullinated peptide antibodies (ACPAs) and rheumatoid factor (RF), are established markers associated with disease severity. Recent studies have identified anti-carbamylated protein (anti-CarP) antibodies as potential indicators of disease progression. Additionally, bone turnover markers and specific single nucleotide polymorphisms (SNPs) may influence RA pathogenesis. This study aimed to evaluate the correlation between autoantibody profiles, disease activity, bone turnover markers, and selected SNPs in a cohort of Polish RA patients.</p></sec><sec id="s2"><title>Material and methods</title><p>A total of 138 RA patients from the Department of Rheumatology, Medical University of Lodz, were enrolled. Disease activity was assessed using the Disease Activity Score in 28 joints by C-reactive protein (DAS28-CRP). Serum levels of RF, ACPAs, anti-CarP antibodies, and bone turnover markers (sclerostin, periostin, and Dickkopf-1) were measured using immunoassays. Genotyping for SNPs in PADI4 (rs2240340), STAT4 (rs7574865), and PTPN22 (rs2476601) genes was performed. Patients were categorized into two groups: those positive for anti-CarP antibodies, RF, and ACPA (triple-positive, <italic toggle="yes">n</italic> = 27) and those with other antibody combinations (<italic toggle="yes">n</italic> = 111).</p></sec><sec id="s3"><title>Results</title><p>Demographic characteristics, including age (mean approx. 61 years), gender distribution (approx. 75% female), treatment rates (approx. 75%), and glucocorticosteroid use (approx. 40%), were comparable between groups. The triple-positive group exhibited higher disease activity, with a greater number of painful joints (mean 10.07 vs. 7.72; <italic toggle="yes">p</italic> = 0.017), higher Visual Analogue Scale (VAS) scores for pain (mean 6.26 vs. 5.06; <italic toggle="yes">p</italic> = 0.018), elevated DAS28-CRP scores (mean 4.75 vs. 4.07; <italic toggle="yes">p</italic> = 0.037), and increased erythrocyte sedimentation rate (ESR) (mean 32.92 mm/h vs. 22.82 mm/h; <italic toggle="yes">p</italic> = 0.019). Serologically, the triple-positive group had significantly higher levels of anti-CarP (mean 29.19 ng/ml vs. 16.29 ng/ml; <italic toggle="yes">p</italic> &lt; 0.0001) and ACPAs (mean 395.45 vs. 368.70; <italic toggle="yes">p</italic> &lt; 0.0001), but lower RF levels (mean 164.01 vs. 453.40; <italic toggle="yes">p</italic> = 0.004). Bone turnover markers showed no significant differences between groups, though the difference in sclerostin levels approached statistical significance (<italic toggle="yes">p</italic> = 0.085), suggesting a possible association of higher bone formation inhibition with triple-positive status. No significant associations were found between the autoantibody profiles and the selected SNPs.</p></sec><sec id="s4"><title>Conclusions</title><p>The presence of anti-CarP antibodies, RF, and ACPA is associated with increased disease activity in RA patients. However, these autoantibody profiles do not significantly correlate with bone turnover markers or the selected genetic polymorphisms in this Polish cohort. Further research is warranted to elucidate the complex interactions between autoantibodies, bone metabolism, and genetic factors in RA.</p></sec></abstract><kwd-group><kwd>rheumatoid arthritis</kwd><kwd>anti-citrullinated peptide antibodies</kwd><kwd>anti-carbamylated protein antibodies</kwd><kwd>bone turnover markers</kwd></kwd-group><funding-group><funding-statement><bold>Funding</bold> This research was funded by the National Science Center (NCN, Poland), grant number UMO-2017/25/B/NZ6/01358.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Rheumatoid arthritis (RA), the most common autoimmune inflammatory disease of the joints, is one of the best-described and understood collagen tissue disorders [<xref rid="cit0001" ref-type="bibr">1</xref>]. However, gaps still exist in our understanding of its pathogenesis and clinical course. Identifying biomarkers that help predict disease severity and endotypes is crucial for both patients and clinicians. One of the most well-described prognostic factors is the presence of autoantibodies, mainly anti-citrullinated peptide antibodies (ACPAs) and rheumatoid factor (RF) [<xref rid="cit0002" ref-type="bibr">2</xref>, <xref rid="cit0003" ref-type="bibr">3</xref>]. The presence of these classical autoantibodies has been linked to 1) faster bone destruction and erosion formation [<xref rid="cit0004" ref-type="bibr">4</xref>], 2) a worse response to treatment [<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0006" ref-type="bibr">6</xref>], 3) potentially worse prognosis, and 4) more pronounced inflammation [<xref rid="cit0006" ref-type="bibr">6</xref>]. However, not all studies confirm these findings [<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>In recent years, several novel autoantibodies have been described and linked to the clinical course of the disease [<xref rid="cit0008" ref-type="bibr">8</xref>, <xref rid="cit0009" ref-type="bibr">9</xref>]. Among them, anti-carbamylated protein (anti-CarP) antibodies seem promising [<xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0010" ref-type="bibr">10</xref>], as they may be linked to disease pathogenesis and exposure to environmental inhalants. Carbamylation refers to the post-translational modification of proteins by the addition of cyanate, resulting in the formation of carbamylated proteins [<xref rid="cit0011" ref-type="bibr">11</xref>]. In RA, this process may contribute to the development and progression of the disease [<xref rid="cit0012" ref-type="bibr">12</xref>]. Proteins such as fibrinogen [<xref rid="cit0013" ref-type="bibr">13</xref>], vimentin [<xref rid="cit0014" ref-type="bibr">14</xref>], and a-enolase [<xref rid="cit0015" ref-type="bibr">15</xref>] are frequently carbamylated in RA. Anti-carbamylated protein antibodies are generated in response to carbamylated peptides. These antibodies contribute to the autoimmune response seen in RA, leading to inflammation and joint damage [<xref rid="cit0012" ref-type="bibr">12</xref>]. Higher levels of anti-CarP antibodies are often associated with increased disease severity in RA patients. Therefore, anti-CarP antibodies may serve as prognostic markers of RA progression [<xref rid="cit0010" ref-type="bibr">10</xref>, <xref rid="cit0016" ref-type="bibr">16</xref>].</p><p>Rheumatoid arthritis is characterized by chronic synovitis leading to enhanced production of pro-inflammatory cytokines and further activation of osteoclasts [<xref rid="cit0001" ref-type="bibr">1</xref>]. Activation of osteoclasts occurs as a result of pro-inflammatory cytokines, which lead to a decrease in the ratio of osteoprotegerin to receptor activator of nuclear factor &#954;B ligand (OPG/RANKL) [<xref rid="cit0017" ref-type="bibr">17</xref>]. In the progression of RA, markers of bone remodeling have been reported to be involved in both bone formation and bone resorption [<xref rid="cit0018" ref-type="bibr">18</xref>]. This phenomenon results in local periarticular osteoporosis and bone erosions, as well as generalized osteoporosis [<xref rid="cit0018" ref-type="bibr">18</xref>]. It has been proven that the degree of bone destruction depends on the activity of joint inflammation; higher inflammation parameters lead to faster progression of bone changes [<xref rid="cit0017" ref-type="bibr">17</xref>, <xref rid="cit0018" ref-type="bibr">18</xref>].</p><p>The etiology of autoimmune diseases, including RA, involves specific interactions between environmental factors and genetic predisposition. The influence of genes from the human leukocyte antigen (HLA) and non-HLA single nucleotide polymorphisms (SNPs) has been demonstrated [<xref rid="cit0019" ref-type="bibr">19</xref>]. Single nucleotide polymorphisms in genes other than HLA are likely involved in RA pathogenesis. Large genome-wide association studies (GWAS) have identified risk factors for RA, with several SNPs in genes including protein tyrosine phosphatase non-receptor type 22 (<italic toggle="yes">PTPN22</italic>, rs2476601), peptidylarginine deiminase type 4 (<italic toggle="yes">PADI4</italic>, rs2240340), tumor necrosis factor associated factor 1 (<italic toggle="yes">TRAF1</italic>, rs3761847), signal transducer and activator of transcription 4 (<italic toggle="yes">STAT4</italic>, rs7574865), and cluster of differentiation 40 (<italic toggle="yes">CD40</italic>, rs4810485) [<xref rid="cit0019" ref-type="bibr">19</xref>&#8211;<xref rid="cit0021" ref-type="bibr">21</xref>]. The products of these genes are involved in RA pathogenesis, providing a reasonable explanation for the role of these SNPs in RA. Studies have confirmed that polymorphisms involving the <italic toggle="yes">PADI4</italic> gene, whose protein is a major factor in citrullination, are present in the Polish RA population [<xref rid="cit0022" ref-type="bibr">22</xref>]. The same was found for the <italic toggle="yes">STAT4</italic> gene, which is involved in inflammation of the synovial joint [<xref rid="cit0023" ref-type="bibr">23</xref>].</p><p>The aim of this study was to assess the correlation of the autoantibody profile with disease activity, bone turnover markers, and the occurrence of selected SNPs in a population of Polish patients with RA.</p></sec><sec sec-type="material|methods" id="sec2"><title>Material and methods</title><sec id="sec2.1"><title>Patients</title><p>The study included patients from the Department of Rheumatology, Medical University of Lodz (Poland) who fulfilled the diagnostic criteria of EULAR/ACR (European Alliance of Associations for Rheumatology/American College of Rheumatology). The study cohort comprised 138 patients diagnosed with RA, with a mean age of 61.29 &#177;13.29 years. The majority were female (<italic toggle="yes">n</italic> = 125), with 13 male participants. Regarding treatment, 108 patients were receiving disease-modifying antirheumatic drugs (DMARDs), including methotrexate (<italic toggle="yes">n</italic> = 79), leflunomide (<italic toggle="yes">n</italic> = 19), sulfasalazine (<italic toggle="yes">n</italic> = 9), and tocilizumab (<italic toggle="yes">n</italic> = 1). Additionally, 61 patients were on glucocorticosteroids (GCs), specifically prednisone. The mean Visual Analogue Scale (VAS) score for pain was 5.27 &#177;2.44 mm. Disease activity, assessed by the Disease Activity Score 28 with C-reactive protein (DAS28-CRP score &#8211; DAS &lt; 1.7 was defined as remission, DAS &gt; 1.7 and &lt; 2.6 was defined as low disease activity, and DAS28 above 5.1 was defined as high disease activity), averaged 4.27 &#177;1.36, with 34 patients (21.66%) exhibiting high disease activity (DAS28-CRP &gt; 5.1). The mean age at symptom onset was 48.99 &#177;14.20 years, and the average disease duration was approximately 12.39 &#177;9.88 months. Inflammatory markers included a mean C-reactive protein (CRP) level of 13.61 &#177;18.09 mg/dl and an erythrocyte sedimentation rate (ESR) of 25.56 &#177;21.24 mm/h.</p></sec><sec id="sec2.2"><title>Sample collection</title><p>Nine milliliters of peripheral blood were collected from patients for serum sample isolation. For DNA isolation, 9 ml of peripheral blood was collected in K3-EDTA tubes. Samples were cryopreserved at &#8211;80&#176;C until the experiments were performed.</p><sec id="s2b1"><title>Analysis of rheumatoid factor and anti-citrullinated protein antibodies</title><p>Rheumatoid factor and ACPAs were measured in a commercial diagnostic laboratory using immunoturbidimetric assay for RF (IU/ml; DxC systems Beckman Coulter) and ELISA for ACPA (RU/ml).</p></sec><sec id="s2b2"><title>Analysis of bone turnover markers</title><p>Protein bone turnover markers were measured in serum samples of RA patients using commercially available enzyme-linked immunosorbent assays (ELISA). For the quantitative measurement of sclerostin (SOST), Dickkopf-1 (DKK-1) and periostin we used the Human SOST ELISA Kit (ab221836-1, ABCAM), Dickkopf-1 measurement was performed using the Human DKK1 ELISA Kit (Dickkopf-1) (ab100501-1, ABCAM), and evaluation of periostin level in serum was performed using the Periostin Human ELISA Kit (EHPOSTN, Thermo Fisher Scientific). For each assay the dilution of the samples had to be optimized. For periostin analysis, the samples were diluted 1 : 3 and 1 : 19 in the case of high concentration (serum : diluent); DKK1 1 : 1; SOST 1 : 1. Assay procedures were followed according to the manuals provided by the manufacturer. Optical density was measured using a plate reader at 450 nm (Multiskan FC Thermo Scientific). Concentrations were automatically interpolated from the standard curve. The results were calculated by multiplying by the dilution factor to determine the final concentrations in serum samples.</p></sec><sec id="s2b3"><title>Analysis of anti-carbamylated peptide antibodies</title><p>For qualitative detection of immunoglobulin G (IgG) antibodies to anti-CarP in patients and the control group we used the Human Anti-Carbamylated Protein Antibody ELISA Kit (BG-HUM09021 NOVATEIN) according to the manufacturer&#8217;s protocol. Values were obtained using formulas present in the protocol. Optical density was measured using a plate reader (Multiskan FC Thermo Scientific) at 450 nm. Values above the 95<sup>th</sup> percentile of healthy donors (&gt; 16.31 ng/ml; <italic toggle="yes">n</italic> = 28) were classified as positive [<xref rid="cit0024" ref-type="bibr">24</xref>].</p></sec></sec><sec id="sec2.3"><title>Genotyping</title><p>Genomic DNA (gDNA) was isolated using the GeneMatrix Blood DNA Purification Kit (EURx, Gdansk, Poland) according to the manufacturer&#8217;s protocol. Genotypes were determined by TaqMan SNP Genotyping Assay as described previously [<xref rid="cit0022" ref-type="bibr">22</xref>].</p></sec><sec id="sec2.4"><title>Statistical analysis</title><p>The statistical analysis was performed using the Statistica 13.3 software package (TIBCO Software Inc.). The normality of data distribution for all continuous variables was assessed with the Shapiro-Wilk test. For variables with a normal distribution and equal variances, Student&#8217;s <italic toggle="yes">t</italic>-test was applied. In cases where these assumptions were not met, the Mann-Whitney <italic toggle="yes">U</italic> test was used. To analyze dichotomous variables and individual genotypes of the studied genes, the &#967;&#178; test and Fisher&#8217;s exact test were utilized. Statistical significance was set at <italic toggle="yes">p</italic> &#8804; 0.05.</p></sec><sec id="sec2.5"><title>Bioethical standards</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Bioethics Committee of the Medical University of Lodz (Poland) (no. RNN/07/18/KE, approved date: 16 January 2018).</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>In this study, 2 patient groups were compared: 1 positive for anti-CarP, RF, and ACPA antibodies (<italic toggle="yes">n</italic> = 27), and another with other combinations of these antibodies (<italic toggle="yes">n</italic> = 111). The 2 groups had similar demographics, including age (mean approx. 61 years), gender distribution (approx. 75% female), treatment rates (approx. 75%), and GCs use (approx. 40%), with no significant differences. However, the triple-positive group exhibited higher disease activity, evidenced by a greater number of painful joints (mean 10.07 vs. 7.72; <italic toggle="yes">p</italic> = 0.0170), higher VAS scores for pain (mean 6.26 vs. 5.06; <italic toggle="yes">p</italic> = 0.0176), elevated Disease Activity Score (DAS) with CRP (mean 4.75 vs. 4.07; <italic toggle="yes">p</italic> = 0.0372), and increased ESR (mean 32.92 mm/h vs. 22.82 mm/h; <italic toggle="yes">p</italic> = 0.0193). Serologically, the triple-positive group had significantly higher levels of anti-CarP (mean 29.19 ng/ml vs. 16.29 ng/ml; <italic toggle="yes">p</italic> &lt; 0.0001) and ACPAs (mean 395.45 vs. 368.70; <italic toggle="yes">p</italic> &lt; 0.0001), but lower RF levels (mean 164.01 vs. 453.40; <italic toggle="yes">p</italic> = 0.0042).</p><sec id="sec3.1"><title>Markers of bone turnover</title><p>The triple-positive group had a mean SOST level of 1,132.26 &#177;404.97 pg/ml, while the other combination group had a mean level of 987.42 &#177;393.72 pg/ml. This difference was not statistically significant (<italic toggle="yes">p</italic> = 0.0850), but suggests that triple-positivity is potentially associated with higher inhibition of bone formation. The mean periostin level was 43.94 &#177;40.65 ng/ml in the triple-positive group and 57.71 &#177;111.04 ng/ml in the other combination group. The difference was not statistically significant (<italic toggle="yes">p</italic> = 0.9179). Also, mean DKK-1 levels did not differ significantly and were 6,206.16 &#177;4,306.75 pg/ml in the triple-positive group and 5,208.03 &#177;2,705.09 pg/ml in the other combination group (<xref rid="t0001" ref-type="table">Table I</xref>).</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table I</label><caption><p>Characteristics of triple-positive vs. non-triple-positive RA patients</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Factor</th><th valign="top" align="center" rowspan="1" colspan="1">Triple positive (anti-CarP+, ACPA+, RF+) (<italic toggle="yes">n</italic> = 27)</th><th valign="top" align="center" rowspan="1" colspan="1">Not triple positive (<italic toggle="yes">n</italic> = 111)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">61.037 &#177;11.044</td><td align="center" rowspan="1" colspan="1">61.712 &#177;13.407</td><td align="center" rowspan="1" colspan="1">0.5583</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex (%)</td><td align="center" rowspan="1" colspan="1">20 (74.07)</td><td align="center" rowspan="1" colspan="1">88 (79.28)</td><td align="center" rowspan="1" colspan="1">0.5565</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment with DMARDs (%)</td><td align="center" rowspan="1" colspan="1">20 (74.07)</td><td align="center" rowspan="1" colspan="1">88 (79.28)</td><td align="center" rowspan="1" colspan="1">0.5565</td></tr><tr><td align="left" rowspan="1" colspan="1">GCs (%)</td><td align="center" rowspan="1" colspan="1">11 (40.74)</td><td align="center" rowspan="1" colspan="1">50 (45.45)</td><td align="center" rowspan="1" colspan="1">0.6588</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of painful joints</td><td align="center" rowspan="1" colspan="1">10.074 &#177;5.784</td><td align="center" rowspan="1" colspan="1">7.721 &#177;6.672</td><td align="center" rowspan="1" colspan="1">0.0170</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of swollen joints</td><td align="center" rowspan="1" colspan="1">4.481 &#177;3.251</td><td align="center" rowspan="1" colspan="1">3.955 &#177;4.832</td><td align="center" rowspan="1" colspan="1">0.1324</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS (0&#8211;10)</td><td align="center" rowspan="1" colspan="1">6.259 &#177;2.263</td><td align="center" rowspan="1" colspan="1">5.064 &#177;2.428</td><td align="center" rowspan="1" colspan="1">0.0176</td></tr><tr><td align="left" rowspan="1" colspan="1">DAS28 &gt; 5.1</td><td align="center" rowspan="1" colspan="1">8 (29.63)</td><td align="center" rowspan="1" colspan="1">26 (24.76)</td><td align="center" rowspan="1" colspan="1">0.6059</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first symptoms [years]</td><td align="center" rowspan="1" colspan="1">47.667 &#177;12.162</td><td align="center" rowspan="1" colspan="1">49.910 &#177;14.684</td><td align="center" rowspan="1" colspan="1">0.3585</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of disease [years]</td><td align="center" rowspan="1" colspan="1">13.370 &#177;8.806</td><td align="center" rowspan="1" colspan="1">11.802 &#177;9.939</td><td align="center" rowspan="1" colspan="1">0.2577</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-CarP &gt; 16.31 [ng/ml]</td><td align="center" rowspan="1" colspan="1">29.187 &#177;13.400</td><td align="center" rowspan="1" colspan="1">16.293 &#177;11.529</td><td align="center" rowspan="1" colspan="1">0.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Periostin [ng/ml]</td><td align="center" rowspan="1" colspan="1">43.936 &#177;40.645</td><td align="center" rowspan="1" colspan="1">57.705 &#177;111.037</td><td align="center" rowspan="1" colspan="1">0.9179</td></tr><tr><td align="left" rowspan="1" colspan="1">Sclerostin [pg/ml]</td><td align="center" rowspan="1" colspan="1">1,132.261 &#177;404.971</td><td align="center" rowspan="1" colspan="1">987.416 &#177;393.723</td><td align="center" rowspan="1" colspan="1">0.0850</td></tr><tr><td align="left" rowspan="1" colspan="1">Dickkopf-1 [pg/ml]</td><td align="center" rowspan="1" colspan="1">6,206.162 &#177;4,306.751</td><td align="center" rowspan="1" colspan="1">5,208.027 &#177;2,705.094</td><td align="center" rowspan="1" colspan="1">0.6768</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-CarP+</td><td align="center" rowspan="1" colspan="1">27 (100)</td><td align="center" rowspan="1" colspan="1">26 (26.80)</td><td align="center" rowspan="1" colspan="1">&lt; 0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-CCP+</td><td align="center" rowspan="1" colspan="1">27 (100)</td><td align="center" rowspan="1" colspan="1">55 (55.00)</td><td align="center" rowspan="1" colspan="1">&lt; 0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RF+</td><td align="center" rowspan="1" colspan="1">27 (100)</td><td align="center" rowspan="1" colspan="1">63 (58.88)</td><td align="center" rowspan="1" colspan="1">&lt; 0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RF [IU/ml]</td><td align="center" rowspan="1" colspan="1">164.013 &#177;245.629</td><td align="center" rowspan="1" colspan="1">453.404 &#177;3,445.928</td><td align="center" rowspan="1" colspan="1">0.0042</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-CCP [RU/ml]</td><td align="center" rowspan="1" colspan="1">395.452 &#177;701.715</td><td align="center" rowspan="1" colspan="1">368.696 &#177;2,587.527</td><td align="center" rowspan="1" colspan="1">0.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">DAS28-CRP</td><td align="center" rowspan="1" colspan="1">4.748 &#177;0.855</td><td align="center" rowspan="1" colspan="1">4.071&#177;1.414</td><td align="center" rowspan="1" colspan="1">0.0372</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP [mg/dl]</td><td align="center" rowspan="1" colspan="1">12.219 &#177;12.662</td><td align="center" rowspan="1" colspan="1">13.686 &#177;19.691</td><td align="center" rowspan="1" colspan="1">0.4386</td></tr><tr><td align="left" rowspan="1" colspan="1">ESR [mm/h]</td><td align="center" rowspan="1" colspan="1">32.923 &#177;25.349</td><td align="center" rowspan="1" colspan="1">22.824 &#177;20.413</td><td align="center" rowspan="1" colspan="1">0.0193</td></tr></tbody></table><table-wrap-foot><fn><p>Anti-CarP &#8211; anti-carbamylated peptide, anti-CCP &#8211; anti-cyclic citrullinated protein, CRP &#8211; C-reactive protein, DAS28 &#8211; Disease Activity Score in 28 joints, DAS28-CRP &#8211; Disease Activity Score in 28 joints by C-reactive protein, DMARDs &#8211; disease-modifying antirheumatic drugs, ESR &#8211; erythrocyte sedimentation rate, GCs &#8211; glucocorticosteroids, RF &#8211; rheumatoid factor, VAS &#8211; Visual Analogue Scale.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.2"><title>Lack of correlations with single nucleotide polymorphisms</title><p>The distribution of genotypes for the SNPs rs2240340, rs3761847, rs7574865, rs4810485, and rs2476601 shows no statistically significant differences between the triple-positive group and the other combination group (<xref rid="t0002" ref-type="table">Table II</xref>).</p><table-wrap position="float" id="t0002" orientation="portrait"><label>Table II</label><caption><p>Presence of SNPs in a cohort of RA patients with different antibody profiles</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Triple-positive patients (anti-CarP, RF and ACPA) (<italic toggle="yes">n</italic> = 24)</th><th valign="top" align="center" rowspan="1" colspan="1">Not triple positive (<italic toggle="yes">n</italic> = 85)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">rs2240340</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;C/T</td><td align="center" rowspan="1" colspan="1">12 (50.00)</td><td align="center" rowspan="1" colspan="1">43 (50.59)</td><td rowspan="3" align="center" colspan="1">0.8656</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T/T</td><td align="center" rowspan="1" colspan="1">5 (22.83)</td><td align="center" rowspan="1" colspan="1">14 (16.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;C/C</td><td align="center" rowspan="1" colspan="1">7 (29.17)</td><td align="center" rowspan="1" colspan="1">28 (32.94)</td></tr><tr><td colspan="4" align="left" rowspan="1">rs3761847</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;A/A</td><td align="center" rowspan="1" colspan="1">6 (25.00)</td><td align="center" rowspan="1" colspan="1">26 (30.59)</td><td rowspan="3" align="center" colspan="1">0.8152</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/G</td><td align="center" rowspan="1" colspan="1">5 (20.83)</td><td align="center" rowspan="1" colspan="1">14 (16.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;A/G</td><td align="center" rowspan="1" colspan="1">13 (54.17)</td><td align="center" rowspan="1" colspan="1">45 (52.94)</td></tr><tr><td colspan="4" align="left" rowspan="1">rs7574865</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/T</td><td align="center" rowspan="1" colspan="1">8 (33.33)</td><td align="center" rowspan="1" colspan="1">34 (40.00)</td><td rowspan="3" align="center" colspan="1">0.6401</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/G</td><td align="center" rowspan="1" colspan="1">13 (54.17)</td><td align="center" rowspan="1" colspan="1">45 (52.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T/T</td><td align="center" rowspan="1" colspan="1">3 (12.50)</td><td align="center" rowspan="1" colspan="1">6 (7.06)</td></tr><tr><td colspan="4" align="left" rowspan="1">rs4810485</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/G</td><td align="center" rowspan="1" colspan="1">15 (62.50)</td><td align="center" rowspan="1" colspan="1">57 (67.06)</td><td rowspan="3" align="center" colspan="1">0.6370</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/T</td><td align="center" rowspan="1" colspan="1">9 (37.50)</td><td align="center" rowspan="1" colspan="1">26 (30.59)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T/T</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (2.35)</td></tr><tr><td colspan="4" align="left" rowspan="1">rs2476601</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/A</td><td align="center" rowspan="1" colspan="1">9 (37.50)</td><td align="center" rowspan="1" colspan="1">24 (28.24)</td><td rowspan="3" align="center" colspan="1">0.5736</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;G/G</td><td align="center" rowspan="1" colspan="1">13 (54.17)</td><td align="center" rowspan="1" colspan="1">56 (65.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;A/A</td><td align="center" rowspan="1" colspan="1">2 (8.33)</td><td align="center" rowspan="1" colspan="1">5 (5.88)</td></tr></tbody></table><table-wrap-foot><fn><p>anti-CarP &#8211; anti-carbamylated peptide antibodies, ACPA &#8211; anti-citrullinated peptide antibodies, RF &#8211; rheumatoid factor.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Our study showed that patients positive for triple autoantibodies &#8211; anti-CarP, RF, and ACPA &#8211; exhibited higher disease activity, as indicated by increased DAS28-CRP scores, VAS pain scores, and ESR levels. This suggests that the presence of multiple autoantibodies may correlate with more severe disease manifestations. These results are in line with previous publications showing that presence of various autoantibodies, especially in high titers, is closely correlated with worse prognosis and prompt disease progression [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0025" ref-type="bibr">25</xref>&#8211;<xref rid="cit0028" ref-type="bibr">28</xref>].</p><p>High levels of RF are known predictor of severe RA [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0029" ref-type="bibr">29</xref>, <xref rid="cit0030" ref-type="bibr">30</xref>]. Patients with both IgM RF and IgG ACPA, commonly referred to as &#8220;double-positive&#8221; patients, tend to experience more significant bone destruction, including more frequent and larger bone erosions. Furthermore, the disease activity is elevated in these double-positive patients, with higher pro-inflammatory cytokine levels compared to patients without RF [<xref rid="cit0031" ref-type="bibr">31</xref>, <xref rid="cit0032" ref-type="bibr">32</xref>]. Anti-carbamylated peptide antibodies are another biomarker linked to RA, often detectable years before the onset of symptoms, and the titers of anti-CarP antibodies tend to rise gradually prior to symptom manifestation, marking them as potential early indicators of RA development in individuals with joint pain [<xref rid="cit0010" ref-type="bibr">10</xref>, <xref rid="cit0033" ref-type="bibr">33</xref>]. They are referred to as predictors of RA onset in people with joint pain [<xref rid="cit0010" ref-type="bibr">10</xref>, <xref rid="cit0011" ref-type="bibr">11</xref>]. These antibodies are associated with accelerated progression of bone lesions, particularly in patients who do not test positive for ACPA [<xref rid="cit0034" ref-type="bibr">34</xref>]. Moreover, research of Kolarz et al. [<xref rid="cit0035" ref-type="bibr">35</xref>] suggested that anti-CarP, but not anti-PAD4, may serve as a valuable biomarker for identifying ACPA/RF-negative RA cases. This makes anti-CarP particularly relevant for diagnosing and assessing RA in these ACPA/RF-negative cases.</p><p>The presence of all 3 antibodies &#8211; RF, ACPA, and anti-CarP &#8211; can be used to identify individuals at risk of developing RA [<xref rid="cit0028" ref-type="bibr">28</xref>, <xref rid="cit0036" ref-type="bibr">36</xref>]. Identifying patients with multiple autoantibodies is therefore essential for tailoring treatment strategies, as these individuals are likely to experience more aggressive disease progression.</p><p>In our study, we hypothesized that patients with triple autoantibody positivity would exhibit significantly elevated markers of bone turnover and regulation. However, this hypothesis was not confirmed. Although the triple-positive group showed higher average sclerostin levels, this was not statistically significant. This difference may nonetheless suggest a potential association of increased bone formation inhibition with triple autoantibody positivity. Given sclerostin&#8217;s role as an inhibitor of the Wnt/&#946;-catenin signaling pathway, which affects bone metabolism, this possibility could have important implications for bone health in RA patients with multiple autoantibodies.</p><p>Sclerostin, a regulator of bone metabolism, is implicated in the pathogenesis of RA and has been found to be present at higher circulating levels in RA patients compared to healthy individuals [<xref rid="cit0037" ref-type="bibr">37</xref>, <xref rid="cit0038" ref-type="bibr">38</xref>]. However, consistent with previous studies, our results did not show a correlation between serum sclerostin levels and disease activity, bone erosions, or other bone biomarkers in RA patients [<xref rid="cit0039" ref-type="bibr">39</xref>]. The correlations with disease activity are not consistently observed in studied cohorts of patients with RA [<xref rid="cit0037" ref-type="bibr">37</xref>].</p><p>Additionally, we did not find any correlation between disease activity and other bone turnover markers such as periostin and DKK-1. Dickkopf-1, an endogenous inhibitor of the canonical Wnt pathway, is implicated in RA pathogenesis. Recent research involving 1,305 RA patients found significantly higher levels of DKK-1 in RA patients compared to controls [<xref rid="cit0040" ref-type="bibr">40</xref>]. Levels of DKK-1 can be linked to structural damage and activity of the disease [<xref rid="cit0041" ref-type="bibr">41</xref>, <xref rid="cit0042" ref-type="bibr">42</xref>]. However, the findings regarding the correlation between ACPAs and DKK-1 are contradictory [<xref rid="cit0042" ref-type="bibr">42</xref>, <xref rid="cit0043" ref-type="bibr">43</xref>].</p><p>Periostin, a matricellular protein involved in tissue development and repair, plays a key role in processes such as cell adhesion, migration, and tissue remodeling, particularly within the extracellular matrix [<xref rid="cit0044" ref-type="bibr">44</xref>]. In RA patients, periostin levels positively correlate with disease activity as assessed by the DAS28 index and with RF and CRP levels [<xref rid="cit0045" ref-type="bibr">45</xref>]. Elevated periostin concentrations may indicate higher disease activity and an increased risk of bone fractures in RA patients [<xref rid="cit0046" ref-type="bibr">46</xref>].</p><p>The lack of significant associations between the studied SNPs linked with RA in the Polish population (rs2240340, rs7574865, and rs2476601) and autoantibody profiles suggests that these genetic variants may not influence the presence of multiple autoantibodies in RA patients [<xref rid="cit0022" ref-type="bibr">22</xref>]. Our findings align with the meta-analysis conducted by Elshazli et al. [<xref rid="cit0047" ref-type="bibr">47</xref>], which demonstrated that polymorphisms in <italic toggle="yes">PTPN22</italic> (rs2476601) and <italic toggle="yes">STAT4</italic> (rs7574865) are associated with increased susceptibility to RA across various ethnic groups, independently of RF and ACPAs status.</p><p>In studies on RA, anti-CarP antibodies were found to be associated with specific genetic variants within the HLA region. Research suggests that HLA-B*08 carrying Asp-9 as the MHC locus is a significant marker for RA patients who test positive for anti-CarP antibodies but negative for ACPAs [<xref rid="cit0048" ref-type="bibr">48</xref>]. Additionally, this antibody profile &#8211; positivity for anti-CarP antibodies and negativity for ACPA &#8211; has been linked to the <italic toggle="yes">HLA-DR3</italic> variant [<xref rid="cit0049" ref-type="bibr">49</xref>&#8211;<xref rid="cit0051" ref-type="bibr">51</xref>]. In contrast, Jiang et al. [<xref rid="cit0052" ref-type="bibr">52</xref>] reported no association between anti-CarP antibodies and most genetic or environmental factors, including smoking, PTPN22 polymorphisms, or general <italic toggle="yes">HLA-DRB1</italic> alleles, except for a specific association between anti-CarP-FCS and the <italic toggle="yes">HLA-DRB1</italic>03* allele. Changes in the levels of RF, ACPA, and anti-CarP antibodies are influenced by the use of DMARDs but do not significantly impact DAS scores [<xref rid="cit0053" ref-type="bibr">53</xref>]. Furthermore, the presence of anti-CarP and ACPA independently affects the progression of RA [<xref rid="cit0054" ref-type="bibr">54</xref>].</p><sec id="sec4.1"><title>Study limitations</title><p>The cross-sectional design of the study limits the ability to infer causal relationships between autoantibody profiles and disease activity or bone turnover. Longitudinal studies are necessary to assess how these factors interact over time. Additionally, investigating other genetic polymorphisms and environmental factors could yield a more comprehensive understanding of their roles in RA pathogenesis and progression. Future plans include expanding the study group for long-term evaluation in a larger cohort of RA patients, with particular emphasis on studies related to SNPs.</p></sec></sec><sec sec-type="conclusions" id="sec5"><title>Conclusions</title><p>Patients positive for anti-CarP, RF, and ACPA antibodies exhibit higher disease activity, as demonstrated by an increased number of painful joints, elevated VAS scores, higher DAS28-CRP scores, and elevated ESR levels. However, no significant association was found between the studied SNPs and disease severity or elevated autoantibody levels. Additionally, bone turnover marker levels did not correlate with the presence of the studied SNPs, disease severity, or the presence of RF, ACPA, and anti-CarP antibodies.</p></sec></body><back><sec><title>Disclosures</title><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><sec><title>Ethics approval</title><p>The study was approved by the Institutional Bioethics Committee of the Medical University of Lodz (Lodz, Poland) (no. RNN/07/18/KE, approved date: 16 January 2018).</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available on request from the corresponding author (J.M.).</p></sec></sec><ref-list id="references"><title>References</title><ref id="cit0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mariani</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Martelli</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Pistone</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pathogenesis of rheumatoid arthritis: one year in review 2023</article-title>. <source>Clin Exp Rheumatol</source><year>2023</year>; <volume>41</volume>: <fpage>1725</fpage>&#8211;<lpage>1734</lpage>, DOI: <pub-id pub-id-type="doi">10.55563/clinexprheumatol/sgjk6e</pub-id>.<pub-id pub-id-type="pmid">37497721</pub-id></mixed-citation></ref><ref id="cit0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smolen</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Landewe</surname><given-names>RBM</given-names></string-name>, <string-name name-style="western"><surname>Bergstra</surname><given-names>SA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update</article-title>. <source>Ann Rheum Dis</source><year>2023</year>; <volume>82</volume>: <fpage>3</fpage>&#8211;<lpage>18</lpage>, DOI: <pub-id pub-id-type="doi">10.1136/ard-2022-223356</pub-id>.<pub-id pub-id-type="pmid">36357155</pub-id></mixed-citation></ref><ref id="cit0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ronnelid</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Turesson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kastbom</surname><given-names>A</given-names></string-name></person-group>. <article-title>Autoantibodies in Rheumatoid Arthritis &#8211; Laboratory and Clinical Perspectives</article-title>. <source>Front Immunol</source><year>2021</year>; <volume>12</volume>: <fpage>685312</fpage>, DOI: <pub-id pub-id-type="doi">10.3389/fimmu.2021.685312</pub-id>.<pub-id pub-id-type="pmid">34054878</pub-id><pub-id pub-id-type="pmcid">PMC8161594</pub-id></mixed-citation></ref><ref id="cit0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vegh</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gaal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Geher</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients</article-title>. <source>BMC Musculoskelet Disord</source><year>2021</year>; <volume>22</volume>: <fpage>325</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s12891-021-04192-x</pub-id>.<pub-id pub-id-type="pmid">33794855</pub-id><pub-id pub-id-type="pmcid">PMC8017697</pub-id></mixed-citation></ref><ref id="cit0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santos-Moreno</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Castro</surname><given-names>C</given-names></string-name></person-group>. <article-title>Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study</article-title>. <source>Medicine (Baltimore</source>) <year>2019</year>; <volume>98</volume>: <fpage>e14181</fpage>, DOI: <pub-id pub-id-type="doi">10.1097/MD.0000000000014181</pub-id><pub-id pub-id-type="pmid">30702571</pub-id><pub-id pub-id-type="pmcid">PMC6380754</pub-id></mixed-citation></ref><ref id="cit0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Albrecht</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zink</surname><given-names>A</given-names></string-name></person-group>. <article-title>Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies</article-title>. <source>Arthritis Res Ther</source><year>2017</year>; <volume>19</volume>: <fpage>68</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s13075-017-1266-4</pub-id>.<pub-id pub-id-type="pmid">28335797</pub-id><pub-id pub-id-type="pmcid">PMC5364634</pub-id></mixed-citation></ref><ref id="cit0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bird</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nicholls</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study</article-title>. <source>Int J Rheum Dis</source><year>2017</year>; <volume>20</volume>: <fpage>460</fpage>&#8211;<lpage>468</lpage>, DOI: <pub-id pub-id-type="doi">10.1111/1756-185X.13036</pub-id>.<pub-id pub-id-type="pmid">28205333</pub-id></mixed-citation></ref><ref id="cit0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sokolova</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Schett</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Steffen</surname><given-names>U</given-names></string-name></person-group>. <article-title>Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings</article-title>. <source>Clin Rev Allergy Immunol</source><year>2022</year>; <volume>63</volume>: <fpage>138</fpage>&#8211;<lpage>151</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s12016-021-08890-1</pub-id>.<pub-id pub-id-type="pmid">34495490</pub-id><pub-id pub-id-type="pmcid">PMC9464122</pub-id></mixed-citation></ref><ref id="cit0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis</article-title>. <source>PLoS One</source><year>2016</year>; <volume>11</volume>: <fpage>e0159000</fpage>, DOI: <pub-id pub-id-type="doi">10.1371/journal.pone.0159000</pub-id>.<pub-id pub-id-type="pmid">27437936</pub-id><pub-id pub-id-type="pmcid">PMC4954701</pub-id></mixed-citation></ref><ref id="cit0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Knevel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Suwannalai</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2011</year>; <volume>108</volume>: <fpage>17372</fpage>&#8211;<lpage>17377</lpage>, DOI: <pub-id pub-id-type="doi">10.1073/pnas.1114465108</pub-id>.<pub-id pub-id-type="pmid">21987802</pub-id><pub-id pub-id-type="pmcid">PMC3198314</pub-id></mixed-citation></ref><ref id="cit0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>van Veelen</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Mahler</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies</article-title>. <source>Autoimmun Rev</source><year>2014</year>; <volume>13</volume>: <fpage>225</fpage>&#8211;<lpage>230</lpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.autrev.2013.10.008</pub-id>.<pub-id pub-id-type="pmid">24176675</pub-id></mixed-citation></ref><ref id="cit0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lopez-Romero</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Martinez-Gamboa</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bang</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN</article-title>. <source>Arthritis Res Ther</source><year>2020</year>; <volume>22</volume>: <fpage>193</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s13075-020-02284-y</pub-id>.<pub-id pub-id-type="pmid">32811536</pub-id><pub-id pub-id-type="pmcid">PMC7437063</pub-id></mixed-citation></ref><ref id="cit0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Diagnostic Value of Antibodies Against Citrullinated or Carbamylated Fibrinogen in Rheumatoid Arthritis</article-title>. <source>Clin Lab</source><year>2020</year>; <volume>66</volume>, DOI: <pub-id pub-id-type="doi">10.7754/Clin.Lab.2020.191256</pub-id>.<pub-id pub-id-type="pmid">32390379</pub-id></mixed-citation></ref><ref id="cit0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ospelt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Feist</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source><year>2017</year>; <volume>76</volume>: <fpage>1176</fpage>&#8211;<lpage>1183</lpage>, DOI: <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-210059</pub-id>.<pub-id pub-id-type="pmid">28183721</pub-id><pub-id pub-id-type="pmcid">PMC5530349</pub-id></mixed-citation></ref><ref id="cit0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reed</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kharlamova</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies</article-title>. <source>Arthritis Res Ther</source><year>2016</year>; <volume>18</volume>: <fpage>96</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s13075-016-1001-6</pub-id>.<pub-id pub-id-type="pmid">27145822</pub-id><pub-id pub-id-type="pmcid">PMC4855497</pub-id></mixed-citation></ref><ref id="cit0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Truchetet</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Dublanc</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barnetche</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of the Presence of Anti-Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome: Data From the French ESPOIR Cohort</article-title>. <source>Arthritis Rheumatol</source><year>2017</year>; <volume>69</volume>: <fpage>2292</fpage>&#8211;<lpage>2302</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.40237</pub-id>.<pub-id pub-id-type="pmid">28853240</pub-id></mixed-citation></ref><ref id="cit0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yokota</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miyazaki</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Characterization and Function of Tumor Necrosis Factor and Interleukin-6-Induced Osteoclasts in Rheumatoid Arthritis</article-title>. <source>Arthritis Rheumatol</source><year>2021</year>; <volume>73</volume>: <fpage>1145</fpage>&#8211;<lpage>1154</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.41666</pub-id>.<pub-id pub-id-type="pmid">33512089</pub-id><pub-id pub-id-type="pmcid">PMC8361923</pub-id></mixed-citation></ref><ref id="cit0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Komatsu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Takayanagi</surname><given-names>H</given-names></string-name></person-group>. <article-title>Mechanisms of joint destruction in rheumatoid arthritis &#8211; immune cell-fibroblast-bone interactions</article-title>. <source>Nat Rev Rheumatol</source><year>2022</year>; <volume>18</volume>: <fpage>415</fpage>&#8211;<lpage>429</lpage>, DOI: <pub-id pub-id-type="doi">10.1038/s41584-022-00793-5</pub-id>.<pub-id pub-id-type="pmid">35705856</pub-id></mixed-citation></ref><ref id="cit0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Padyukov</surname><given-names>L</given-names></string-name></person-group>. <article-title>Genetics of rheumatoid arthritis</article-title>. <source>Semin Immunopathol</source><year>2022</year>; <volume>44</volume>: <fpage>47</fpage>&#8211;<lpage>62</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s00281-022-00912-0</pub-id>.<pub-id pub-id-type="pmid">35088123</pub-id><pub-id pub-id-type="pmcid">PMC8837504</pub-id></mixed-citation></ref><ref id="cit0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbasifard</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Imani</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bagheri-Hosseinabadi</surname><given-names>Z</given-names></string-name></person-group>. <article-title>PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis</article-title>. <source>J Gene Med</source><year>2020</year>; <volume>22</volume>: <fpage>e3204</fpage>, DOI: <pub-id pub-id-type="doi">10.1002/jgm.3204</pub-id>.<pub-id pub-id-type="pmid">32333475</pub-id></mixed-citation></ref><ref id="cit0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tizaoui</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>GH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Genetic Polymorphism of PTPN22 in Autoimmune Diseases: A Comprehensive Review</article-title>. <source>Medicina (Kaunas</source>) <year>2022</year>; <volume>58</volume>: <fpage>1034</fpage>, DOI: <pub-id pub-id-type="doi">10.3390/medicina-58081034</pub-id>.<pub-id pub-id-type="pmid">36013501</pub-id><pub-id pub-id-type="pmcid">PMC9415475</pub-id></mixed-citation></ref><ref id="cit0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Budlewski</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sarnik</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Galita</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>SNP in PTPN22, PADI4, and STAT4 but Not TRAF1 and CD40 Increase the Risk of Rheumatoid Arthritis in Polish Population</article-title>. <source>Int J Mol Sci</source><year>2023</year>; <volume>24</volume>: <fpage>7586</fpage>, DOI: <pub-id pub-id-type="doi">10.3390/ijms24087586</pub-id>.<pub-id pub-id-type="pmid">37108746</pub-id><pub-id pub-id-type="pmcid">PMC10145319</pub-id></mixed-citation></ref><ref id="cit0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frucht</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Aringer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Galon</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation</article-title>. <source>J Immunol</source><year>2000</year>; <volume>164</volume>: <fpage>4659</fpage>&#8211;<lpage>4664</lpage>, DOI: <pub-id pub-id-type="doi">10.4049/jimmunol.164.9.4659</pub-id>.<pub-id pub-id-type="pmid">10779770</pub-id></mixed-citation></ref><ref id="cit0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iacono</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Favoino</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Borgia</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence</article-title>. <source>Open Access Rheumatol</source><year>2018</year>; <volume>10</volume>: <fpage>129</fpage>&#8211;<lpage>134</lpage>, DOI: <pub-id pub-id-type="doi">10.2147/OARRR.S163731</pub-id>.<pub-id pub-id-type="pmid">30233261</pub-id><pub-id pub-id-type="pmcid">PMC6132236</pub-id></mixed-citation></ref><ref id="cit0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scherer</surname><given-names>HU</given-names></string-name>, <string-name name-style="western"><surname>Haupl</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Burmester</surname><given-names>GR</given-names></string-name></person-group>. <article-title>The etiology of rheumatoid arthritis</article-title>. <source>J Autoimmun</source><year>2020</year>; <volume>110</volume>: <fpage>102400</fpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.jaut.2019.102400</pub-id>.<pub-id pub-id-type="pmid">31980337</pub-id></mixed-citation></ref><ref id="cit0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sokolove</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Lahey</surname><given-names>LJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis</article-title>. <source>Arthritis Rheumatol</source><year>2014</year>; <volume>66</volume>: <fpage>813</fpage>&#8211;<lpage>821</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.38307</pub-id>.<pub-id pub-id-type="pmid">24757134</pub-id><pub-id pub-id-type="pmcid">PMC3994896</pub-id></mixed-citation></ref><ref id="cit0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alivernini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galeazzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peleg</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons</article-title>. <source>Autoimmun Rev</source><year>2017</year>; <volume>16</volume>: <fpage>1096</fpage>&#8211;<lpage>1102</lpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.autrev.2017.09.002</pub-id>.<pub-id pub-id-type="pmid">28899798</pub-id></mixed-citation></ref><ref id="cit0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verheul</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Bohringer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Delft</surname><given-names>MAM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals</article-title>. <source>Arthritis Rheumatol</source><year>2018</year>; <volume>70</volume>: <fpage>1721</fpage>&#8211;<lpage>1731</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.40562</pub-id>.<pub-id pub-id-type="pmid">29781231</pub-id></mixed-citation></ref><ref id="cit0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Zeben</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hazes</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Zwinderman</surname><given-names>AH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study</article-title>. <source>Ann Rheum Dis</source><year>1992</year>; <volume>51</volume>: <fpage>1029</fpage>&#8211;<lpage>1035</lpage>, DOI: <pub-id pub-id-type="doi">10.1136/ard.51.9.1029</pub-id>.<pub-id pub-id-type="pmid">1417131</pub-id><pub-id pub-id-type="pmcid">PMC1004831</pub-id></mixed-citation></ref><ref id="cit0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vastesaeger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford</source>) <year>2009</year>; <volume>48</volume>: <fpage>1114</fpage>&#8211;<lpage>1121</lpage>, DOI: <pub-id pub-id-type="doi">10.1093/rheumatology/kep155</pub-id>.<pub-id pub-id-type="pmid">19589891</pub-id></mixed-citation></ref><ref id="cit0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bobbio-Pallavicini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Caporali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alpini</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients</article-title>. <source>Ann N Y Acad Sci</source><year>2007</year>; <volume>1109</volume>: <fpage>287</fpage>&#8211;<lpage>295</lpage>, DOI: <pub-id pub-id-type="doi">10.1196/annals.1398.034</pub-id>.<pub-id pub-id-type="pmid">17785317</pub-id></mixed-citation></ref><ref id="cit0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Witalison</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Hofseth</surname><given-names>LJ</given-names></string-name></person-group>. <article-title>Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation</article-title>. <source>Curr Drug Targets</source><year>2015</year>; <volume>16</volume>: <fpage>700</fpage>&#8211;<lpage>710</lpage>, DOI: <pub-id pub-id-type="doi">10.2174/1389450116666150202160954</pub-id>.<pub-id pub-id-type="pmid">25642720</pub-id><pub-id pub-id-type="pmcid">PMC4520219</pub-id></mixed-citation></ref><ref id="cit0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aggarwal</surname><given-names>BB</given-names></string-name></person-group>. <article-title>Signalling pathways of the TNF superfamily: a double-edged sword</article-title>. <source>Nat Rev Immunol</source><year>2003</year>; <volume>3</volume>: <fpage>745</fpage>&#8211;<lpage>756</lpage>, DOI: <pub-id pub-id-type="doi">10.1038/nri1184</pub-id>.<pub-id pub-id-type="pmid">12949498</pub-id></mixed-citation></ref><ref id="cit0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Webb</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Seaman</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis</article-title>. <source>Immunol Res</source><year>2015</year>; <volume>61</volume>: <fpage>24</fpage>&#8211;<lpage>30</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s12026-014-8560-x</pub-id>.<pub-id pub-id-type="pmid">25391608</pub-id></mixed-citation></ref><ref id="cit0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kolarz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ciesla</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname><given-names>AK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients</article-title>. <source>Ther Adv Musculoskelet Dis</source><year>2021</year>; <volume>13</volume>: <fpage>1759720X21989868</fpage>, DOI: <pub-id pub-id-type="doi">10.1177/1759720X21989868</pub-id>.<pub-id pub-id-type="pmcid">PMC7882754</pub-id><pub-id pub-id-type="pmid">33628335</pub-id></mixed-citation></ref><ref id="cit0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koppejan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Trouw</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Sokolove</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls</article-title>. <source>Arthritis Rheumatol</source><year>2016</year>; <volume>68</volume>: <fpage>2090</fpage>&#8211;<lpage>2098</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.39664</pub-id>.<pub-id pub-id-type="pmid">26946484</pub-id><pub-id pub-id-type="pmcid">PMC6680251</pub-id></mixed-citation></ref><ref id="cit0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaskiewicz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chmielewski</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kuna</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Role of Sclerostin in Rheumatic Diseases: A Review</article-title>. <source>J Clin Med</source><year>2023</year>; <volume>12</volume>: <fpage>6248</fpage>, DOI: <pub-id pub-id-type="doi">10.3390/jcm12196248</pub-id>.<pub-id pub-id-type="pmid">37834893</pub-id><pub-id pub-id-type="pmcid">PMC10573925</pub-id></mixed-citation></ref><ref id="cit0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>QL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis</article-title>. <source>Z Rheumatol</source><year>2023</year>; <volume>82</volume> (<issue>Suppl 1</issue>): <fpage>51</fpage>&#8211;<lpage>58</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s00393-021-01091-3</pub-id>.<pub-id pub-id-type="pmid">34545431</pub-id></mixed-citation></ref><ref id="cit0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fayed</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Elgohary</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fawzy</surname><given-names>M</given-names></string-name></person-group>. <article-title>Evaluating the role of serum sclerostin as an indicator of activity and damage in Egyptian patients with rheumatoid arthritis: university hospital experience</article-title>. <source>Clin Rheumatol</source><year>2020</year>; <volume>39</volume>: <fpage>1121</fpage>&#8211;<lpage>1130</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s10067-019-04878-7</pub-id>.<pub-id pub-id-type="pmid">31865506</pub-id></mixed-citation></ref><ref id="cit0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis</article-title>. <source>Int Immunopharmacol</source><year>2018</year>; <volume>59</volume>: <fpage>227</fpage>&#8211;<lpage>232</lpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.intimp.2018.04.019</pub-id>.<pub-id pub-id-type="pmid">29665496</pub-id></mixed-citation></ref><ref id="cit0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis</article-title>. <source>J Rheumatol</source><year>2011</year>; <volume>38</volume>: <fpage>821</fpage>&#8211;<lpage>827</lpage>, DOI: <pub-id pub-id-type="doi">10.3899/jrheum.100089</pub-id>.<pub-id pub-id-type="pmid">21362762</pub-id></mixed-citation></ref><ref id="cit0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ali</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Esmail</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Mohammed</surname><given-names>HA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Serum Dickkopf-1 as a potential prognostic marker in patients with rheumatoid arthritis</article-title>. <source>Egyptian Rheumatology and Rehabilitation</source><year>2021</year>; <volume>48</volume>: <fpage>42</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s43166-021-00088-9</pub-id>.</mixed-citation></ref><ref id="cit0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aydemir</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Akgol</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gulkesen</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical correlation and determination of Dkk-1 and sclerostin levels in patients with rheumatoid arthritis</article-title>. <source>Medicine Science</source><year>2020</year>; <volume>9</volume>: <fpage>1053</fpage>&#8211;<lpage>1060</lpage>, DOI: <pub-id pub-id-type="doi">10.5455/medscience.2020.06.097</pub-id>.</mixed-citation></ref><ref id="cit0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bonnet</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Garnero</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ferrari</surname><given-names>S</given-names></string-name></person-group>. <article-title>Periostin action in bone</article-title>. <source>Mol Cell Endocrinol</source><year>2016</year>; <volume>432</volume>: <fpage>75</fpage>&#8211;<lpage>82</lpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.mce.2015.12.014</pub-id>.<pub-id pub-id-type="pmid">26721738</pub-id></mixed-citation></ref><ref id="cit0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Identification of serological biomarkers for diagnosis of rheumatoid arthritis using a protein array- based approach</article-title>. <source>Nan Fang Yi Ke Da Xue Xue Bao</source><year>2022</year>; <volume>42</volume>: <fpage>733</fpage>&#8211;<lpage>739</lpage><comment>[Article in Chinese]</comment>.<pub-id pub-id-type="pmid">35673918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12122/j.issn.1673-4254.2022.05.15</pub-id><pub-id pub-id-type="pmcid">PMC9178634</pub-id></mixed-citation></ref><ref id="cit0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kerschan-Schindl</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ebenbichler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Foeger-Samwald</surname><given-names>U</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rheumatoid arthritis in remission: Decreased myostatin and increased serum levels of periostin</article-title>. <source>Wien Klin Wochenschr</source><year>2019</year>; <volume>131</volume>: <fpage>1</fpage>&#8211;<lpage>7</lpage>, DOI: <pub-id pub-id-type="doi">10.1007/s00508-018-1386-0</pub-id>.<pub-id pub-id-type="pmcid">PMC6342879</pub-id><pub-id pub-id-type="pmid">30171335</pub-id></mixed-citation></ref><ref id="cit0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elshazil</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Settin</surname><given-names>A</given-names></string-name></person-group>. <article-title>Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update</article-title>. <source>Immunobiology</source><year>2015</year>; <volume>220</volume>: <fpage>1012</fpage>&#8211;<lpage>1024</lpage>, DOI: <pub-id pub-id-type="doi">10.1016/j.imbio.2015.04.003</pub-id>.<pub-id pub-id-type="pmid">25963842</pub-id></mixed-citation></ref><ref id="cit0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Regueiro</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Casares-Marfil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lundberg</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>HLA-B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis</article-title>. <source>Arthritis Rheumatol</source><year>2021</year>; <volume>73</volume>: <fpage>963</fpage>&#8211;<lpage>969</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.41630</pub-id>.<pub-id pub-id-type="pmid">33381897</pub-id></mixed-citation></ref><ref id="cit0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>SF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis</article-title>. <source>Int J Mol Sci</source><year>2021</year>; <volume>22</volume>: <fpage>686</fpage>, DOI: <pub-id pub-id-type="doi">10.3390/ijms22020686</pub-id>.<pub-id pub-id-type="pmid">33445768</pub-id><pub-id pub-id-type="pmcid">PMC7828258</pub-id></mixed-citation></ref><ref id="cit0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Regueiro</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Rodriguez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Triguero-Martinez</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis</article-title>. <source>Arthritis Rheumatol</source><year>2019</year>; <volume>71</volume>: <fpage>331</fpage>&#8211;<lpage>339</lpage>, DOI: <pub-id pub-id-type="doi">10.1002/art.40738</pub-id>.<pub-id pub-id-type="pmid">30277011</pub-id></mixed-citation></ref><ref id="cit0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwon</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Ju</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Impact of Posttranslational Modification in Pathogenesis of Rheumatoid Arthritis: Focusing on Citrullination, Carbamylation, and Acetylation</article-title>. <source>Int J Mol Sci</source><year>2021</year>; <volume>22</volume>: <fpage>10576</fpage>, DOI: <pub-id pub-id-type="doi">10.3390/ijms221910576</pub-id>.<pub-id pub-id-type="pmid">34638916</pub-id><pub-id pub-id-type="pmcid">PMC8508717</pub-id></mixed-citation></ref><ref id="cit0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Trouw</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>van Wesemael</surname><given-names>TJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies</article-title>. <source>Ann Rheum Dis</source><year>2014</year>; <volume>73</volume>: <fpage>1761</fpage>&#8211;<lpage>1768</lpage>, DOI: <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-205109</pub-id>.<pub-id pub-id-type="pmid">24812286</pub-id></mixed-citation></ref><ref id="cit0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Moel</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Derksen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Trouw</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response</article-title>. <source>Arthritis Res Ther</source><year>2019</year>; <volume>21</volume>: <fpage>28</fpage>, DOI: <pub-id pub-id-type="doi">10.1186/s13075-019-1815-0</pub-id>.<pub-id pub-id-type="pmid">30658699</pub-id><pub-id pub-id-type="pmcid">PMC6339446</pub-id></mixed-citation></ref><ref id="cit0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akdemir</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Verheul</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Heimans</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study</article-title>. <source>RMD Open</source><year>2016</year>; <volume>2</volume>: <fpage>e000172</fpage>, DOI: <pub-id pub-id-type="doi">10.1136/rmdopen-2015-000172</pub-id>.<pub-id pub-id-type="pmid">26925251</pub-id><pub-id pub-id-type="pmcid">PMC4762208</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>